$CCEL
CRYO CELL INTERNATIONAL INC

2018 Q4 Form 10-K Financial Statement

#000119312520056695 Filed on February 28, 2020

View on sec.gov

Income Statement

Concept 2018 Q4 2018 2017 Q4
Revenue $8.594M $29.22M $6.470M
YoY Change 32.82% 15.1% 10.22%
Cost Of Revenue $2.675M $8.540M $1.640M
YoY Change 63.1% 27.0% 13.89%
Gross Profit $5.919M $20.68M $4.840M
YoY Change 22.29% 10.82% 9.26%
Gross Profit Margin 68.87% 70.77% 74.81%
Selling, General & Admin $4.120M $15.63M $3.540M
YoY Change 16.37% 15.96% -7.09%
% of Gross Profit 69.6% 75.6% 73.14%
Research & Development $26.92K $91.85K $20.00K
YoY Change 34.6% 123.11% 0.0%
% of Gross Profit 0.45% 0.44% 0.41%
Depreciation & Amortization $103.1K $317.3K $60.00K
YoY Change 71.75% 37.97% -14.29%
% of Gross Profit 1.74% 1.53% 1.24%
Operating Expenses $4.202M $15.72M $3.590M
YoY Change 17.04% 16.29% -6.99%
Operating Profit $1.717M $5.189M $1.250M
YoY Change 37.36% 3.66% 119.3%
Interest Expense -$551.5K $1.547M -$370.0K
YoY Change 49.04% 18.75% 164.29%
% of Operating Profit -32.12% 29.81% -29.6%
Other Income/Expense, Net -$39.24K -$1.572M -$20.00K
YoY Change 96.2% 13.68% -166.67%
Pretax Income $1.542M $3.618M $860.0K
YoY Change 79.26% -0.17% 145.71%
Income Tax $557.7K $4.473M $180.0K
% Of Pretax Income 36.18% 123.63% 20.93%
Net Earnings $890.8K -$854.8K $680.0K
YoY Change 30.99% -136.92% -16.05%
Net Earnings / Revenue 10.37% -2.93% 10.51%
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share $114.2K -$0.11 $89.24K
COMMON SHARES
Basic Shares Outstanding 7.801M shares 7.463M 7.103M shares
Diluted Shares Outstanding 7.463M

Balance Sheet

Concept 2018 Q4 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.916M $6.916M $6.720M
YoY Change 2.91% 2.94% 63.11%
Cash & Equivalents $6.040M $6.040M $6.279M
Short-Term Investments $875.7K $875.7K $440.0K
Other Short-Term Assets $254.5K $716.3K $206.1K
YoY Change 23.45% 23.86% 162.77%
Inventory $1.261M $1.261M $314.6K
Prepaid Expenses $461.8K $372.2K
Receivables $5.867M $5.867M $5.126M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $14.76M $14.76M $12.74M
YoY Change 15.88% 15.88% 41.33%
LONG-TERM ASSETS
Property, Plant & Equipment $1.493M $1.493M $882.4K
YoY Change 69.25% 69.25% -9.91%
Goodwill $1.941M $0.00
YoY Change
Intangibles $1.341M $226.4K
YoY Change 492.42% -13.25%
Long-Term Investments $308.0K $308.0K
YoY Change
Other Assets $26.14M $22.55M $10.29M
YoY Change 153.99% 124.02% 7.79%
Total Long-Term Assets $28.13M $27.63M $11.17M
YoY Change 151.73% 147.29% 6.14%
TOTAL ASSETS
Total Short-Term Assets $14.76M $14.76M $12.74M
Total Long-Term Assets $28.13M $27.63M $11.17M
Total Assets $42.89M $42.39M $23.91M
YoY Change 79.36% 77.29% 22.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.262M $1.262M $1.929M
YoY Change -34.58% -34.58% 29.83%
Accrued Expenses $2.703M $2.703M $2.582M
YoY Change 4.66% 4.66% 1.1%
Deferred Revenue $8.365M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $2.000M
YoY Change 55.0% 55.0% 0.0%
Total Short-Term Liabilities $15.43M $15.43M $13.94M
YoY Change 10.69% 10.69% 6.32%
LONG-TERM LIABILITIES
Long-Term Debt $1.425M $9.844M $1.425M
YoY Change 0.0% 85.9% 0.0%
Other Long-Term Liabilities $35.87M $26.03M $22.47M
YoY Change 59.61% 51.5% 2.89%
Total Long-Term Liabilities $37.29M $35.87M $23.90M
YoY Change 56.05% 59.61% 2.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.43M $15.43M $13.94M
Total Long-Term Liabilities $37.29M $35.87M $23.90M
Total Liabilities $51.30M $51.30M $36.41M
YoY Change 40.88% 40.88% 4.18%
SHAREHOLDERS EQUITY
Retained Earnings -$25.33M -$24.47M
YoY Change 3.49% -8.64%
Common Stock $35.65M $31.50M
YoY Change 13.17% 3.4%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.57M $19.57M
YoY Change 0.0% 2.34%
Treasury Stock Shares $5.801M 5.801M shares
Shareholders Equity -$8.908M -$8.908M -$12.50M
YoY Change
Total Liabilities & Shareholders Equity $42.39M $42.39M $23.91M
YoY Change 77.29% 77.29% 22.37%

Cashflow Statement

Concept 2018 Q4 2018 2017 Q4
OPERATING ACTIVITIES
Net Income $890.8K -$854.8K $680.0K
YoY Change 30.99% -136.92% -16.05%
Depreciation, Depletion And Amortization $103.1K $317.3K $60.00K
YoY Change 71.75% 37.97% -14.29%
Cash From Operating Activities $844.0K $5.333M $2.110M
YoY Change -60.0% -6.73% -17.9%
INVESTING ACTIVITIES
Capital Expenditures -$37.86K $446.2K -$40.00K
YoY Change -5.35% 353.73% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$31.06K -$10.64M $30.00K
YoY Change -203.53% -5658.24% -200.0%
Cash From Investing Activities -$68.93K -$11.28M -$20.00K
YoY Change 244.65% -12228.36% -71.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.775M 5.710M -480.0K
YoY Change 269.79% -288.33% -52.94%
NET CHANGE
Cash From Operating Activities 844.0K 5.333M 2.110M
Cash From Investing Activities -68.93K -11.28M -20.00K
Cash From Financing Activities -1.775M 5.710M -480.0K
Net Change In Cash -999.9K -239.1K 1.610M
YoY Change -162.11% -108.6% 8.78%
FREE CASH FLOW
Cash From Operating Activities $844.0K $5.333M $2.110M
Capital Expenditures -$37.86K $446.2K -$40.00K
Free Cash Flow $881.8K $4.887M $2.150M
YoY Change -58.98% -13.04% -17.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-11-30
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Trading Symbol
TradingSymbol
CCEL
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7545613
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541037
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6040033
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
904053
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
875689
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
500260
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
461815
CY2019Q4 us-gaap Inventory Net
InventoryNet
1084533
CY2018Q4 us-gaap Inventory Net
InventoryNet
1260557
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
260397
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
254465
CY2019Q4 us-gaap Assets Current
AssetsCurrent
15387611
CY2018Q4 us-gaap Assets Current
AssetsCurrent
14759894
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1846467
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1493401
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1249254
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1341336
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12646000
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
14775316
CY2019Q4 us-gaap Goodwill
Goodwill
1941411
CY2018Q4 us-gaap Goodwill
Goodwill
1941411
CY2019Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9079994
CY2018Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
7656897
CY2019Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
427423
CY2018Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
113888
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25652082
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26136848
CY2019Q4 us-gaap Assets
Assets
42886160
CY2018Q4 us-gaap Assets
Assets
42390143
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1369111
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1261653
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2085180
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2702788
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429429
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429725
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3495057
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
4282975
CY2019Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2018Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34409582
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35868716
CY2019Q4 us-gaap Liabilities
Liabilities
49839011
CY2018Q4 us-gaap Liabilities
Liabilities
51298441
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
135989
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
135964
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35918827
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35515382
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
340984
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22444310
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25329515
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6952851
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8908298
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42886160
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42390143
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2584091
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2264848
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91845
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13598909
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7510884
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13596409
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7800833
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31816571
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29218490
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10036175
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8539662
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14891462
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15632696
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30145
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
206238
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
180264
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
26753865
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
24029187
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32155
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24723
CY2019 us-gaap Interest Expense
InterestExpense
1703446
CY2018 us-gaap Interest Expense
InterestExpense
1546900
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1671291
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1571623
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3391415
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3617680
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7794828
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7463051
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8412414
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7463051
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2290774
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-554705
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-12502896
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3670925
CY2019 us-gaap Profit Loss
ProfitLoss
2290774
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
401311
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
317326
CY2019 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-162307
CY2019 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-742918
CY2018 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-415280
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
397770
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
478378
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
767128
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
727483
CY2019 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1517289
CY2018 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
2378491
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
112642
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
109292
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
997124
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1347773
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
38445
CY2018 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
20796
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
27423
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6323207
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5333330
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-316650
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
5932
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
48329
CY2019 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-15696
CY2018 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
85000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
107458
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-666889
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-599200
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
120313
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3825996
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4095416
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
662295
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
446163
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
200000
CY2019 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
28364
CY2018 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
136248
CY2018 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
10500000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-690659
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11282411
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4100000
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3291665
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5700
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
170925
CY2018 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
9000000
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
169300
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5131544
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5709960
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
501004
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-239121
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6279154
CY2019Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
-340984
CY2018 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
20103661
CY2018 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
1405406
CY2018 us-gaap Profit Loss
ProfitLoss
-854824
CY2019 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Warranty and Cryo-Cell Cares<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">TM</div> Program </div></div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#160;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June&#160;1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. </div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at November&#160;30, 2019. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
329231
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
398535
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6097331
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5867335
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8875138
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8365284
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23633373
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20317231
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
478378
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-854824
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5700
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
397770
CY2019 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
253447
CY2019 us-gaap Net Income Loss
NetIncomeLoss
2290774
CY2019Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
32508511
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2019 ccel Allocated Share Based Compensation Expenses Reversed
AllocatedShareBasedCompensationExpensesReversed
444000
CY2019Q4 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2
CY2019Q4 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
8875138
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2019 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
35300
CY2018Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
329231
CY2018Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
66533
CY2019 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
87518
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2018 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2018 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
28000
CY2018 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
300000
CY2019 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
28000
CY2018 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
31388278
CY2018 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
2658679
CY2018 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.36
CY2018 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.36
CY2019Q1 ccel Cumulative Effect Adjustment From Accumulated Other Comprehensive Income To Retained Earnings
CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings
341000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Risks </div></div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate. </div></div><div style="font-size: 1px; margin-top: 12px; margin-bottom: 0px; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-size: 1px; font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available. </div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units.&#160;However, the Company believes that alternative sources of supply and manufacturing are available. </div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant. </div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2019 and 2018, there were no concentration of risks. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 4%; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q2 dei Entity Public Float
EntityPublicFloat
30374581
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-854824
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
617586
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2019 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
992244
CY2018 ccel Increase Decrease In Goodwill
IncreaseDecreaseInGoodwill
66565
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
992244
CY2019Q4 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2019Q4 us-gaap Notes Payable
NotesPayable
9108433
CY2018Q4 us-gaap Notes Payable
NotesPayable
13208433
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
152281
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
264923
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
8956152
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
12943510
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5856152
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9843510
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
646744
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
589583
CY2019 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
112642
CY2018 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
109293
CY2019 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
759386
CY2018 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
698876
CY2019 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
The Company depends on one supplier for the source of its collection kits
CY2019 us-gaap Advertising Expense
AdvertisingExpense
981448
CY2018 us-gaap Advertising Expense
AdvertisingExpense
986664
CY2019 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
832587
CY2018 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
671245
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
398000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
478000
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2019Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13730533
CY2018Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
16035873
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1249254
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1341336
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
67667
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
67667
CY2019 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15
CY2019 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
205000
CY2018 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
158000
CY2019 ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2019Q4 ccel Inventory Collection Kits
InventoryCollectionKits
44453
CY2018Q4 ccel Inventory Collection Kits
InventoryCollectionKits
19163
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
67667
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
67667
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
67667
CY2019Q4 ccel Finite Lived Intangible Assets Amortization Expense Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseThereafter
910919
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
92000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
76000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
228148
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
224928
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
18744
CY2014Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17600
CY2018Q3 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
322984
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
312307
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
40254
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.06
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
143409
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.02
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
58429
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.36
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
125234
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.70
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
5062706
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
5189303
CY2019 us-gaap Interest Expense
InterestExpense
1703446
CY2018 us-gaap Interest Expense
InterestExpense
1546900
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1100641
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4472504
CY2019 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
CY2018 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
300119
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2098991
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
907263
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
345637
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
756688
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
308803
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8300883
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7116711
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8963178
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6807482
CY2019 us-gaap Depreciation
Depreciation
309000
CY2018 us-gaap Depreciation
Depreciation
241000
CY2019 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
195000
CY2018 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
137000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1637000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1467000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
769000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
622000
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
108000
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
108000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2514000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2197000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1106000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2716000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-307000
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-441000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1413000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2275000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
6256000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5157000
CY2019Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1224000
CY2018Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1214000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
82000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
257000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1589000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
868000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
411000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
330000
CY2019Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
450000
CY2018Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
428000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
18000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
18000
CY2019Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1095000
CY2019Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
513108
CY2018Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1210000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11125000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9482000
CY2019Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
117000
CY2018Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
112000
CY2019Q4 ccel Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses
-282000
CY2018Q4 ccel Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses
-79000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
399000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
191000
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0632
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1646000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1634000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
9080000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
7657000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
115000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
14867
CY2018Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1021004
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
950300
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
216608
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
711000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
3100000
CY2019 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50
CY2018 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
733198
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
799507
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2210
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
220527
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
864676
CY2019Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1089774
CY2019Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.30
CY2019Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
964540
CY2019Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.75
CY2019 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y10M27D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
CY2014Q2 ccel Operating Lease Period
OperatingLeasePeriod
P10Y
CY2019 ccel Types Of License Agreements
TypesOfLicenseAgreements
2
CY2019Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
330726
CY2018Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
478449
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
176046
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
323792
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0599
CY2019 ccel Effective Income Tax Rate Reconciliation Valuation Allowances
EffectiveIncomeTaxRateReconciliationValuationAllowances
0.0000
CY2018 ccel Effective Income Tax Rate Reconciliation Valuation Allowances
EffectiveIncomeTaxRateReconciliationValuationAllowances
0.0000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
26330
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0075
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
260845
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0721
CY2019 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
76775
CY2019 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0220
CY2018 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
149141
CY2018 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0412
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
3078094
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.8508
CY2019 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
24533
CY2019 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
-0.0070
CY2018 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
-28337
CY2018 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.0078
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
19278
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0010
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-3354
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0009
CY2019 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
108150
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0310
CY2018 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
108314
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0299
CY2018 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.0299
CY2019 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
108150
CY2019 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.0310
CY2018 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
108314
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1100641
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3087
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4472504
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.2363
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3100000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
3100000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2908433
CY2019 dei Security12b Title
Security12bTitle
Common Stock
CY2019 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
2801000
CY2018 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
2204000
CY2019 dei Security Exchange Name
SecurityExchangeName
NONE
CY2019 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod
30000
CY2018 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cash Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCashPayments
444000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company&#8217;s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2018 and the remaining 1/3 on November 30, 2019
CY2019 ccel Payment Of Earnout
PaymentOfEarnout
45000
CY2019 us-gaap Cumulative Effect On Retained Earnings Tax1
CumulativeEffectOnRetainedEarningsTax1
94192

Files In Submission

Name View Source Status
0001193125-20-056695-index-headers.html Edgar Link pending
0001193125-20-056695-index.html Edgar Link pending
0001193125-20-056695.txt Edgar Link pending
0001193125-20-056695-xbrl.zip Edgar Link pending
ccel-20191130.xml Edgar Link completed
ccel-20191130.xsd Edgar Link pending
ccel-20191130_cal.xml Edgar Link unprocessable
ccel-20191130_def.xml Edgar Link unprocessable
ccel-20191130_lab.xml Edgar Link unprocessable
ccel-20191130_pre.xml Edgar Link unprocessable
d807043d10k.htm Edgar Link pending
d807043dex311.htm Edgar Link pending
d807043dex312.htm Edgar Link pending
d807043dex313.htm Edgar Link pending
d807043dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g807043g0228054232370.jpg Edgar Link pending
g807043g0228054232542.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending